Spotlight Growth
No Result
View All Result
Friday, February 3, 2023
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
No Result
View All Result
No Result
View All Result
Home Cannabis

OWC Pharmaceutical Research Corp. (OTCQB: OWCP) Declined 14.13% After Reporting Second Quarter 2017 Earnings

by admin
August 21, 2017
in Cannabis, Earnings
0
OWC Pharmaceutical Research Corp. (OTCQB: OWCP) Declined 14.13% After Reporting Second Quarter 2017 Earnings

Cannabis Medical Research Israel Earnings

OWC Pharmaceutical Research Corp. (OTCQB: OWCP) is engaged as an Israeli cannabis and medical research company. Shares of the medical testing company closed down 14.13%, during trading on Monday, August 21, 2017. Over the past month, OWC Pharmaceutical Research Corp. has seen average daily volume of 1.23 million shares. However, volume of 1.07 million shares or dollar volume of $338,120, exchanged hands during today’s trading.

Shares of OWC Pharmaceutical Research Corp. saw pressure today, after the company reported second quarter 2017 earnings results. The company reported no revenues and a net loss of $447,961 during the second quarter. On a six-month basis, the Israeli cannabis company reported no revenues and net losses exceeded $1.88 million. While OWC Pharmaceutical Research Corp. did not report any revenue during the same time last year, the company is seeing its expenses grow sharply compared to a year ago. On the other hand, the company lists total assets of $1.41 million, total liabilities of $175,619, and total stockholders’ equity of $1.24 million.

OWCP Q217 and 6-Month Income Statement
OWCP Q217 and 6-Month Income Statement

 

Ballooning expenses are even more noticeable when looking at the total results from the first six months, compared to last year. Through the end of June 2017, OWC Pharmaceutical Research Corp. has seen its net loss grow to a total of $1.88 million. This compares to a 6-month net loss of $488,118, during the same period last year. The company must continue to watch its expanding costs and expenses, which are only hitting the bottom line. There continues to be a lack of clarity on when the company can specifically start generating regular revenues, but there is no doubt a very strong and committed shareholder base for OWC Pharmaceutical Research Corp. out there.

 

Here is the link to the full 10-Q earnings report: http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12244229

Tags: biopharmaceuticalsbiotechcannabisclinical trialscommon stockearningsemerging growthFDAfinancialsIsraelmarijuana stocksmedical cannabismedical marijuanamicrocap stockspharmaceuticalspublic companyresearchsmall cap companiessmall cap stockssmall capsSpotlight GrowthSpotlight Growth Stockstreatment
  • Trending
  • Comments
  • Latest
Asure Software NASDAQ ASUR Human Capital Management HCM Industry Spotlight Growth

Asure Software (NASDAQ: ASUR) is Expanding to Meet the Rising Demand for Human Capital Management Software

September 27, 2022
OLB Group NASDAQ OLB Cuentas NASDAQ CUEN Partnership Fintech Spotlight Growth

OLB Group (NASDAQ: OLB) and Cuentas (NASDAQ: CUEN) Team Up to Bring Fintech Solutions to Over 32,000 Bodegas Across the United States

October 6, 2022
Siyata Mobile NASDAQ SYTA SYTAW SD7 VK7 Purchase Orders Spotlight Growth

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

December 14, 2021
Telcoin TEL Crypto Spotlight Growth

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

June 15, 2021
Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

0
Safe-T SFET NASDAQ UN Presentation

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

0
Safe-T Group SFET Q4 FY 2020 Financial Results

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

0
Safe-T Group NASDAQ SFET FY 2020 Prelim

Safe-T Group Ltd. (NASDAQ: SFET) Estimates Record-High Annual Revenues of Approximately $4.9 Million Representing ~50% Growth YoY 2020

0
Elys Game Technology Corp NASDAQ ELYS Completes Acquisition of Engage IT Services Spotlight Growth

Elys Game Technology Corp (NASDAQ: ELYS) Completes Acquisition of Engage IT Services, a Software Engineering and IT Development Company

February 2, 2023
Tenax Therapeutics NASDAQ TENX US Patent Levosimendan PH-HFpEF Spotlight Growth

Tenax Therapeutics (NASDAQ: TENX) Granted U.S. Patent for IV Levosimendan for Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

February 2, 2023
Versus Systems NASDAQ VS Resolve Debt Partner AI Gamification Consumer Debt Spotlight Growth

Versus Systems (NASDAQ: VS) and Resolve Debt Partner to Integrated Generative AI and Gamification to Customer Payments and Credit Markets

February 1, 2023
Finding the Most Accurate Technical Analysis Indicator Spotlight Growth

Finding the Most Accurate Technical Analysis Indicator

January 31, 2023
ADVERTISEMENT

Recent News

Elys Game Technology Corp NASDAQ ELYS Completes Acquisition of Engage IT Services Spotlight Growth

Elys Game Technology Corp (NASDAQ: ELYS) Completes Acquisition of Engage IT Services, a Software Engineering and IT Development Company

February 2, 2023
Tenax Therapeutics NASDAQ TENX US Patent Levosimendan PH-HFpEF Spotlight Growth

Tenax Therapeutics (NASDAQ: TENX) Granted U.S. Patent for IV Levosimendan for Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

February 2, 2023

Categories

  • Bio/Med/Pharma
  • Cannabis
  • Commodities
  • Consumer Goods
  • Crowdfunding
  • Crypto Cheat Sheets
  • Cryptocurrency
  • Earnings
  • Education
  • Entertainment
  • Financials
  • Market News
  • Opinion
  • Politics
  • Real Estate
  • Split Watch
  • Sponsored
  • Store
  • Technology
  • Uncategorized
  • Venture Capital/Private Equity (VC/PE)

Site Navigation

  • Disclosures
  • Terms Of Service
  • Privacy Policy
  • Contact Us

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

No Result
View All Result
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

Newsletter Signup

Subscribe to our weekly newsletter below and never miss the latest small/micro-cap analysis and investment news from Spotlight Growth.

Enter your email address

Thanks, I’m not interested